(Q48400646)

11 February 2018

title

Ebselen attenuates reserpine-induced orofacial dyskinesia and oxidative stress in rat striatum (English)

1 reference

11 February 2018

1 reference

1 reference

5

1 reference

11 February 2018

Gilson Zeni

6

1 reference

11 February 2018

Joao Batista da Rocha

7

1 reference

11 February 2018

Marilise Escobar Burger

1

object named as

Marilise E Burger

1 reference

11 February 2018

author name string

Audrei Alves

2

1 reference

11 February 2018

Luciano Callegari

3

1 reference

11 February 2018

Fernanda R Athayde

4

1 reference

11 February 2018

publication date

1 February 2003

1 reference

11 February 2018

Progress in Neuro-Psychopharmacology & Biological Psychiatry

published in

1 reference

11 February 2018

volume

27

1 reference

11 February 2018

issue

1

1 reference

11 February 2018

page(s)

135-140

1 reference

11 February 2018

Effects of melatonin on orofacial movements in rats

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900344-5

7 January 2021

Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats. Implications for tardive dyskinesia?

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900344-5

7 January 2021

Effects of age on a new animal model of tardive dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900344-5

7 January 2021

The mitochondrial toxin 3-nitropropionic acid aggravates reserpine-induced oral dyskinesia in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900344-5

7 January 2021

The neuroprotective efficacy of ebselen (a glutathione peroxidase mimic) on brain damage induced by transient focal cerebral ischaemia in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900344-5

7 January 2021

Behavioral effects of MK-801 on reserpine-treated mice

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900344-5

7 January 2021

Treatment of tardive dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900344-5

7 January 2021

Vitamin E in the treatment of tardive dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900344-5

7 January 2021

Mixture in the distribution of haloperidol-induced oral dyskinesias in the rat supports an animal model of tardive dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900344-5

7 January 2021

Ebselen protects both gray and white matter in a rodent model of focal cerebral ischemia

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900344-5

7 January 2021

The pharmacology of tardive dyskinesias

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900344-5

7 January 2021

Tardive dyskinesia: An update

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900344-5

7 January 2021

Oxygen radicals and neuropsychiatric illness. Some speculations

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900344-5

7 January 2021

Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900344-5

7 January 2021

Kinetic mechanism and substrate specificity of glutathione peroxidase activity of ebselen (PZ51).

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900344-5

7 January 2021

The antioxidant ebselen prevents neurotoxicity and clinical symptoms in a primate model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900344-5

7 January 2021

Chemistry of biologically important synthetic organoselenium compounds.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900344-5

7 January 2021

A novel biologically active seleno-organic compound—1

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900344-5

7 January 2021

Excitatory mechanisms in neuroleptic-induced vacuous chewing movements (VCMs): possible involvement of calcium and nitric oxide

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900344-5

7 January 2021

Ebselen reduces cytochrome c release from mitochondria and subsequent DNA fragmentation after transient focal cerebral ischemia in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900344-5

7 January 2021

Neurochemical changes associated with the persistence of spontaneous oral dyskinesia in rats following chronic reserpine treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900344-5

7 January 2021

Dose-dependent differences in the development of reserpine-induced oral dyskinesia in rats: support for a model of tardive dyskinesia.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900344-5

7 January 2021

Effects of amphetamine and 6-hydroxydopamine lesions on reserpine-induced oral dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900344-5

7 January 2021

Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900344-5

7 January 2021

Ebselen prevents excitotoxicity provoked by glutamate in rat cerebellar granule neurons.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900344-5

7 January 2021

Effects of buspirone on an animal model of tardive dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900344-5

7 January 2021

Reversal of reserpine-induced vacuous chewing movements in rats by melatonin: involvement of peripheral benzodiazepine receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900344-5

7 January 2021

Ebselen blocks the quinolinic acid-induced production of thiobarbituric acid reactive species but does not prevent the behavioral alterations produced by intra-striatal quinolinic acid administration in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900344-5

7 January 2021

Antioxidant properties of new chalcogenides against lipid peroxidation in rat brain.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900344-5

7 January 2021

The current status of tardive dyskinesia.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900344-5

7 January 2021

Neuroprotective effect of an antioxidant, ebselen, in patients with delayed neurological deficits after aneurysmal subarachnoid hemorrhage

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900344-5

7 January 2021

Melatonin treatment for tardive dyskinesia: a double-blind, placebo-controlled, crossover study

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900344-5

7 January 2021

Acute reserpine administration elicits long-term spontaneous oral dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900344-5

7 January 2021

Neuroprotective efficacy of ebselen, an anti-oxidant with anti-inflammatory actions, in a rodent model of permanent middle cerebral artery occlusion

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900344-5

7 January 2021

Study on the suitability of a rat model for tardive dyskinesia and the preventive effects of various drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900344-5

7 January 2021

Ebselen in acute ischemic stroke: a placebo-controlled, double-blind clinical trial. Ebselen Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900344-5

7 January 2021

Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900344-5

7 January 2021

The vacuous chewing movement (VCM) model of tardive dyskinesia revisited: is there a relationship to dopamine D(2) receptor occupancy?

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900344-5

7 January 2021

Effects of monosialoganglioside on dopaminergic supersensitivity.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900344-5

7 January 2021

Effects of monosialoganglioside on a new model of tardive dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900344-5

7 January 2021

Effects of haloperidol and GM1 ganglioside treatment on striatal D2 receptor binding and dopamine turnover

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900344-5

7 January 2021

Spontaneous orofacial movements induced in rodents by very long-term neuroleptic drug administration: phenomenology, pathophysiology and putative relationship to tardive dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900344-5

7 January 2021

Can the supersensitivity of rodents to dopamine be regarded as a model of tardive dyskinesia?

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900344-5

7 January 2021

10.1016/S0278-5846(02)00344-5

Identifiers

DOI

1 reference

11 February 2018

1 reference

11 February 2018